We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Abbott (ABT - Free Report) closed at $103.09 in the latest trading session, marking a +1.12% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.48%. Elsewhere, the Dow saw a downswing of 0.29%, while the tech-heavy Nasdaq depreciated by 0.56%.
The stock of maker of infant formula, medical devices and drugs has fallen by 8.36% in the past month, lagging the Medical sector's loss of 2.01% and the S&P 500's loss of 0.82%.
The upcoming earnings release of Abbott will be of great interest to investors. The company is expected to report EPS of $1.43, up 10% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $12.91 billion, indicating a 13.52% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.52 per share and a revenue of $50.32 billion, signifying shifts of +7.18% and +13.51%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Abbott. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.03% higher within the past month. Abbott is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 18.46. This valuation marks a discount compared to its industry average Forward P/E of 20.16.
Meanwhile, ABT's PEG ratio is currently 1.89. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 1.75 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
Abbott (ABT - Free Report) closed at $103.09 in the latest trading session, marking a +1.12% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.48%. Elsewhere, the Dow saw a downswing of 0.29%, while the tech-heavy Nasdaq depreciated by 0.56%.
The stock of maker of infant formula, medical devices and drugs has fallen by 8.36% in the past month, lagging the Medical sector's loss of 2.01% and the S&P 500's loss of 0.82%.
The upcoming earnings release of Abbott will be of great interest to investors. The company is expected to report EPS of $1.43, up 10% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $12.91 billion, indicating a 13.52% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.52 per share and a revenue of $50.32 billion, signifying shifts of +7.18% and +13.51%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Abbott. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.03% higher within the past month. Abbott is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 18.46. This valuation marks a discount compared to its industry average Forward P/E of 20.16.
Meanwhile, ABT's PEG ratio is currently 1.89. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 1.75 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.